文献速递中毒与环境急症重症综合管理与镇静镇痛

托特罗定中毒与管理:458例病例系列

Tropatepine poisoning and management: a series of 458 cases.
PubMed 文献 · Clin Toxicol (Phila) · 2026-01-20
一句话结论回顾性多中心458例显示,托特罗定中毒中枢抗胆碱能症状中位持续24小时,毒扁豆碱对中枢症状的完全缓解率显著高于新斯的明(OR 6.61)。

该研究为法国中毒中心2000年1月1日至2023年7月13日报告的托特罗定中毒回顾性多中心研究,共纳入458例。外周和中枢抗胆碱能体征分别见于214例(46.7%)和102例(22.3%);单药摄入者(n=94)中29例(30.8%)出现激越或谵妄。报告的中位摄入剂量270 mg与中枢及外周抗胆碱能体征出现相关,而仅外周体征者为100 mg(P=0.0012)。中枢抗胆碱能体征中位持续24小时(IQR 12-48小时)。激越分别有25例和13例使用新斯的明和毒扁豆碱治疗;新斯的明组16例(76%)中枢体征无改善,毒扁豆碱组13例(100%)反应良好;调整摄入剂量后,毒扁豆碱组中枢抗胆碱能体征完全缓解的几率显著高于新斯的明组(OR 6.61;95%CI 1.00-44.94;P=0.0499)。

要点

  • 458例托特罗定中毒中,中枢抗胆碱能体征见于102例(22.3%),中位持续24小时(IQR 12-48小时)。
  • 单药摄入者(n=94)中29例(30.8%)出现激越或谵妄。
  • 报告的中位摄入剂量270 mg与中枢及外周抗胆碱能体征出现相关,仅外周体征者为100 mg(P=0.0012)。
  • 新斯的明治疗者16例(76%)中枢体征无改善,毒扁豆碱治疗者13例(100%)反应良好。
  • 调整摄入剂量后,毒扁豆碱组中枢抗胆碱能体征完全缓解几率显著高于新斯的明组(OR 6.61;95%CI 1.00-44.94;P=0.0499)。

适用人群与场景

  • 法国中毒中心2000年1月1日至2023年7月13日报告的托特罗定中毒病例,共458例。
  • 单药摄入托特罗定者94例。

处置流程与药物剂量

  • 激越分别使用新斯的明(25例)和毒扁豆碱(13例)治疗;原文未报告具体剂量、给药途径和频次。

研究设计与关键结果

  • 研究类型为流行病学、回顾性、多中心研究,纳入458例托特罗定中毒病例。
  • 外周和中枢抗胆碱能体征分别见于214例(46.7%)和102例(22.3%)。
  • 单药摄入者(n=94)中29例(30.8%)出现激越或谵妄。
  • 报告的中位摄入剂量270 mg与中枢及外周抗胆碱能体征出现相关,仅外周体征者为100 mg(P=0.0012)。
  • 中枢抗胆碱能体征中位持续24小时(IQR 12-48小时)。
  • 新斯的明组16例(76%)中枢体征无改善,毒扁豆碱组13例(100%)反应良好。
  • 调整摄入剂量后,毒扁豆碱组中枢抗胆碱能体征完全缓解几率显著高于新斯的明组(OR 6.61;95%CI 1.00-44.94;P=0.0499)。

证据类型、等级与局限

  • 证据类型:回顾性多中心流行病学研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为毒扁豆碱虽仍少用,但似乎能有效控制托特罗定所致中枢抗胆碱能综合征。
  • 托特罗定中毒因消除半衰期长,常伴随严重且持久的抗胆碱能综合征,护理激越患者需要大量护理人员投入。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Tropatepine is an antiparkinsonian drug that can be associated with antimuscarinic delirium in overdose. Two acetylcholinesterase inhibitors, neostigmine and physostigmine, are available for the management of tropatepine poisoning. The aim of this study is to describe a series of tropatepine poisonings and to compare the management of patients.

METHODS: This epidemiological, retrospective, multicentre study reviewed tropatepine intoxications reported to French poison centres from 1 January 2000 to 13 July 2023. The relationship between reduction in central antimuscarinic signs and associated risk factors was assessed by univariate and multivariate logistic regression.

RESULTS: A total of 458 cases of tropatepine poisoning were included. Peripheral and central antimuscarinic signs were observed in 214 (46.7%) and 102 patients (22.3%), respectively. For patients who ingested tropatepine alone (n = 94), 29 (30.8%) showed agitation or delirium. A reported median ingested dose of 270 mg of tropatepine was associated with the onset of central and peripheral antimuscarinic signs, compared with 100 mg for peripheral signs alone (P = 0.0012). The median (IQR) duration of central antimuscarinic signs was 24 h (12-48 h). Agitation was treated by neostigmine and physostigmine in 25 and 13 patients, respectively. In 16 (76%) patients treated with neostigmine, there was no improvement in central signs, whereas 13 (100%) patients responded favorably to physostigmine. After adjustment for ingested dose, the complete resolution of central antimuscarinic signs was significantly higher in patients treated with physostigmine than with neostigmine (odds ratio 6.61; 95% CI: 1.00-44.94]; P = 0.0499).

DISCUSSION: Due to its long elimination half-life, tropatepine poisoning is frequently associated with a severe and prolonged antimuscarinic syndrome. Caring for these agitated patients requires substantial input from nursing staff.

CONCLUSIONS: Physostigmine is still little used but appears to be effective in controlling the central antimuscarinic syndrome induced by tropatepine.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Tireau E, Descatha A, Deguigne M, et al. Tropatepine poisoning and management: a series of 458 cases. Clin Toxicol (Phila). 2026. PMID: 41557478. doi:10.1080/15563650.2025.2605131

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。